Congrats Katie Campbell !!!

NO kidney rejection, durable efficacy. Big signal for this population with high unmet need! #ASCO #ASCO2023

Encouraging anti-tumor activity for patients w/metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGFβ inhibitor BCA101 w/pembrolizumab. Dose expansion results reported by Dana-Farber's Glenn Hanna, MD, (Glenn J. Hanna, M.D.) at #ASCO23.

This incredible group made it through Sunday's humidity to run & finish the B.A.A. 10K race. Congratulations to all, and thank you for supporting the Brigham! #BAA10K

Further evidence to support TTMV-HPV DNA testing to monitor HPV+ oropharyngeal cancer. With longer term follow-up, NPV is >98%. Accuracy metrics rival that of surveillance imaging 🧐👀🧪🧬 Naveris, Inc. Eleni Rettig Ask About HPV Dana-Farber Dana-Farber News aacrjournals.org/clincancerres/…

Subset of exhausted TIL responds to ICB in HNSCC. Read our summary and interview with the researcher => bit.ly/3tbvQ4l @danafarber Harvard Medical School

Excited to share our paper on the first small molecule inhibitors of PTPN2/PTPN1 for cancer immunotherapy out today in nature nature.com/articles/s4158… This has been a collaboration with Calico and AbbVie. Very proud of the amazing team that made this happen! Explainer below👇

So proud of our colleagues Rob Manguso for this phenomenal work! Enrolling patients now based on👇@danafarber_ccti (NCT04777994) #hncsm #lcsm #scchn #kcsm #hnscc #NSCLC Glenn J. Hanna, M.D. Mark Awad Robert Haddad Charlene Mantia Toni Choueiri, MD Geoffrey Shapiro MD PhD Ravi Uppaluri, MDPhD Dana-Farber News

Eleni Rettig reviewing the potential power of HPV ctDNA across the spectrum of disease in HPV+ OPC — at the Boston HNC Symposium 🧐🧬🧪Ravi Uppaluri, MDPhD Naveris, Inc. Dana-Farber News Dana-Farber Faden Lab Boston University

Boston H&N symposium today with many great speakers. Nabil Saba, MD Eleni Rettig Glenn J. Hanna, M.D. Robert Haddad Dr. Chris Holsinger Dana-Farber

Dr. Shin Saito from Ravi Uppaluri, MDPhD lab of Dana-Farber reveals that targeting dendritic cell dysfunction circumvents anti PD-1 resistance in head and neck squamous cell carcinoma, offering a strategy to enhance HNSCC's sensitivity to immune checkpoint inhibitors(ICIs).#IOTNSCMeeting

Sharing our work using aPD-1 immunotherapy for oral precancer prevention in high-risk oral leukoplakia now published in JAMA Oncology🧐‼️🔎 Ravi Uppaluri, MDPhD Alessandro Villa, DDS, PhD, MPH UC San Diego Health Dana-Farber Dana-Farber News jamanetwork.com/journals/jamao…

Enormously proud of Ian for stepping into this role. Huge congratulations!!

Out today--DC dysfunction in HNSCC antiPD1 resistance w/ a mechanistic role for CCL5 in enhancing DC function/ T cell priming. Congrats to Shin/Michi! Brigham and Women’s Department of Surgery Dana-Farber News Robert Haddad Glenn J. Hanna, M.D. Jonathan Schoenfeld tinyurl.com/686af9e9

Great work from Anthony Anthony Wang and colleagues on this study! Allegra Petti MGH Neurosurgery MGHNeuroOncology Mass General Cancer Center Harvard Immunology Washington University Neurosurgery @WUSTLlImmuno

Amazing keynote lecture by Ravi Uppaluri, MDPhD Dana-Farber on the potential power of #neoadjuvant #immunotherapy in resectable #headandneckcancer at #hncs24 ASTRO AHNS ASCO

Thanks R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) !

Please join the AHNS webinar. We have an amazing group of trailblazing researchers giving us insight to the science and clinical applications of immunotherapy in head and neck cancer. Sana Karam, MD, PhD Ravi Uppaluri, MDPhD Carissa M Thomas MD PhD Tullia Bruno, PhD

Thank you Dartmouth 🌲 for the invitation and incredible honor to deliver the commencement speech to the 2024 graduating class 🌲#Dartmouth24s

Stella Lee, MD, and her team are carving a path to cleaner air and healthier noses and sinuses at the Brigham. Learn more: bwhclinicalandresearchnews.org/2024/04/23/wha…